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ABSTRACT 
 A collaborative effort of clinicians, infectologists, molecular biologists, pharmacologists, 
veterinarians, bioinformaticians, management and education specialists is united in order to 
develop novel strategies of detecting early stages of chronic and infective diseases, their 
prevention and therapy. CODI-STRAT integrates 15 centers conducting leading–edge 
research of chronic inflammatory/infective diseases from seven European (five 
Mediterranean) countries and the USA, with specific aims to: i) establish long-standing 
partner center cross-disciplinary collaborations for clinical studies and research,  ii) provide 
young investigators with broad and content-driven training and employability and iii) 
promote scientists up-skilled in genomics, transcriptomics, tissue expression, human 
serological and genetic studies, bioinformatics, chip technology, cell cultures and animal 
models, all directed toward clinical translation and chronic/infective disease management. 
This manuscript outlines the goals, partner roles and development of CODI-STRAT and its 
programme. 
 
Keywords: Prevention/treatment strategies, management of chronic/infective diseases, 
inflammation/infection, multicenter/multidisciplinary consortium   
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INTRODUCTION 
CODI-STRAT consortium is an international, multicenter, interdisciplinary network of 
research, clinical and education centers formed in order to provide advancement of knowledge 
and innovation in anti-inflammatory/anti-infective strategies. The network bridges 
interdisciplinary partners with the major aims to detect chronic diseases at earlier stages, 
identify optimal markers, monitor, and treat chronic diseases with innovative therapies. This 
platform will be supplemented with molecular, cellular, serological, immunological, 
biopharmaceutical technologies, as well as FACS, microarrays, qPCR, bioinformatics and 
mathematical modeling. High-quality non-scientific training will complement the research 
portfolio with management, patent issues, entrepreneurial skills and strategic planning for 
industrial collaborations.  
Background 
The world’s elderly population, more prone to chronic disease, is growing. The result is a 
quiet epidemic of chronic illness that causes 86 % of deaths in Europe (WHO press release 
EURO/05/06, Copenhagen, 2006), which could largely be preventable (Figure 1).  
Worldwide Share of Deaths in 2002, by Cause 
Figure 1: Colin D. 
Mathers et al., "The 
Global Burden of 
Disease in 2002: Data 
Sources, Methods, and 
Results," GPE 
Discussion Paper 54 
(Geneva: World Health 
Organization, 2003), 
available at 
www.who.int/evidence
. 
 
Chronic inflammation represents the underlying cause and driving force for the development 
and exacerbation of the majority of chronic diseases (Weiss U., 2008), such as rheumatoid 
arthritis (RA), asthma and persistent viral/bacterial infections leading to great economic 
(worldwide average: 3% of gross domestic product) and social burden. In developing 
countries the economic impact is additionally greater because many people with chronic 
illnesses are of working age.  
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In addition, many approved anti-inflammatory drugs, such as leflunomide, methotrexate, non-
steroidal anti-inflammatory drugs, biologicals and clinical trials of novel potential anti-
inflammatory therapies have shown a variety of undesirable side-effects (e.g. patients prone to 
infections). More financial and human resources are urgently needed to optimize treatments 
and detection methods that could greatly benefit a wide range of diseases and improve patient 
health. In the past few decades the drive towards new therapies for chronic diseases has 
strongly increased in the U.S., as compared to Europe. This is currently changing and thus 
there will be a demand for well-trained clinicians, immunologists, molecular and cellular 
biologists, pharmacologists, veterinarians, bioinformaticians and management specialists in 
the chronic anti-inflammatory and anti-infective fields.  
The mission/vision of the network is the long-term collaboration of a trans-Mediterranean, 
European, as well as international network for first-rate research and training of young 
investigators in the advancement of chronic disease knowledge, innovation and prevention, 
while providing a base for efficient, mutually beneficial collaborations and enabling expedited 
knowledge, information, technology and reagent transfer. Overcoming difficulties in data 
interpretation, wasteful duplication and competition, while increasing productivity, is a 
priority of the network. A computer and information technology support system is planned for 
the science, training and transfer of knowledge activities. 
 
General Outline of CODI-STRAT 
Studies have recently reported the necessity for early detection/diagnosis leading to better 
prognosis and outcome of chronic inflammatory diseases (Medzhitov R., 2008; Galli S.J. et 
al., 2008). Infections can cause and/or lead to the exacerbation of chronic inflammatory 
conditions, while on the other hand, chronic inflammatory diseases can also lead to the 
susceptibility of the organism to infections. Both infectious diseases and inflammation share 
common cellular/molecular/biochemical pathways. One of these pathways involves acute 
phase reactants in mammals.  
Major acute phase proteins can represent excellent tools for early inflammatory disease 
detection, diagnosis, progression determination and outcome. Serum amyloid A (SAA), as 
one of the two major acute phase proteins in humans, can be elevated up to 1000-fold during 
inflammation and can represent a key driving force during the longitudinal progression of 
disease and tissue remodelling. SAA is not only an early and sensitive marker of 
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inflammation, tissue trauma and infection, it is also an excellent clinical biomarker (Malle E. 
and F.C. de Beer, 1996; Cunnane G. et al., 2000), following disease activity and, in a number 
of pathologies, can predict mortality (Morrow D.A. et al., 2000). SAA is especially implicated 
in chronic inflammatory diseases, such as rheumatoid arthritis (RA), atherosclerosis, 
cardiovascular diseases and cancers (Lakota K. et al., 2010). SAA is considered a better 
predictor of clinical progression and outcome than CRP in RA (Cunnane G. et al., 2000) and 
is a predictive and prognostic marker of certain cardiovascular diseases and cancers 
(Katayama T. et al., 2005; Morrow D.A. et al., 2000; Johnson B.D. et al., 2004; Malle E. et 
al., 2009). 
SAA at physiological concentrations is further known to be an active participant in 
homeostasis, endowed with beneficial properties in protection against viral and bacterial 
infections (Lavie M. et al., 2006; Shah C. et al., 2006; Hari-Dass R. et al., 2005) and is 
necessary in host defense. On the other hand, sustained SAA levels occur during chronic 
inflammation and promote tissue degradation (Sodin-Semrl S. et al., 2004) (Figure 2).  
 
 
 
 
 
 
 
 
Figure 2: A critical event in the inflammatory process is activation of “para-inflammatory” 
transitional phase leading to chronic signaling, which, if unregulated, can result in persistent 
stimulation of pro-inflammatory mediators. Some acute phase reactants, such as Serum amyloid A 
(SAA) act as a molecular switch in the early regulation of inflammation. Among the objectives of 
CODI-STRAT are the development of strategies that would identify early inflammatory molecules 
needed to be targeted, as well as test existing and novel anti-inflammatory mediators. 
 
As an acute-phase protein, SAA acts similarly in humans and mice, making mice models 
accessible. This has not been the case with the classical inflammatory marker, C-reactive 
protein (CRP). In certain autoimmune diseases, such as systemic lupus erythematosus, 
ulcerative colitis, CRP does not show elevated levels, during an obvious presence of 
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inflammation (Wettero J., 2008; Sjowall C., 2007), so SAA can represent the more optimal 
inflammatory biochemical marker. In children’s infections (such as measles, varicella, 
rubella, mumps, echo-30 meningitis, chronic hepatitis B and C, and in some Kawasaki cases), 
56% of patients had raised SAA concentrations while CRP was not increased above normal 
levels (Miwata H. et al., 1993). However, CRP is still routinely used as the only routine 
biochemical marker of inflammation. 
 
In comparison with human studies, the veterinary science, as evident at the last International 
meeting on acute-phase proteins in Helsinki 2010 and also from recent publications (Eckersall 
P.D. and R. Bell, 2010) has already identified, recognized and used SAA as a standard non-
specific marker of disease, disease activity and outcome, making SAA a protein with huge 
commercial potential. There is considerable evidence that SAA has a protective role against 
infection for instance when SAA is made in large amounts in milk following inflammatory 
stimuli in many animals, such as cows and swine (Molenaar A.J. et al., 2009; de Jesus 
Rodriguez B. et al., 2009). SAA itself is however, relatively easily degraded and if the protein 
is to be used in a therapeutic way to help control infection then it is important to understand 
which regions of the protein need to be retained and others that can be changed to increase 
stability or bioavailability. CODI-STRAT proposes that development of reagents, detection 
kits, and a deeper understanding of acute phase reactants, e.g. SAA and its biology will 
generate technology to measure SAA more reliably, for instance through measurements of a 
specific isoform or epitope; generating know-how which will impact the development of 
novel anti-inflammatory and anti-infective drugs. These efforts/approaches will help to clarify 
the biological roles associated with this acute-phase reactant. So, we deem timely to 
investigate the properties of SAA, providing standard detection of SAA in diseases and 
enabling development of therapies based on its functions.  
 
Brief overview of work programme and objectives 
The strength of this network is the integration of core basic research with high-throughput 
techniques, bioinformatic analyses and biopharmaceutical compounds coupled with cellular, 
animal and human serological studies. The scientific project scheme is presented in Figure 3. 
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Figure 3: CODI-STRAT 
A multi-disciplinary approach 
for earlier detection and future 
prevention of chronic diseases 
 
In order to achieve the network’s main aim of developing novel anti-inflammatory and anti-
infective strategies, the following specific research objectives are proposed: 
1. Identification of novel inflammatory markers and SAA genetic variants and their 
contribution to clinical phenotypic characteristics of asthma. Determination of the likely 
effects of SAA genetic variability on anti-inflammatory, antiviral, antibacterial and 
immunotherapeutic efficacy will be evaluated. SAA genetic variation studies will provide 
information with benefits, as part of a pharmacogenetic profiling system, for potential future 
anti-asthma therapies based on SAA inhibition. 
2. Detection of very early stages of inflammation. SAA has been previously shown to 
correlate best with markers of RA activity, as compared to CRP or erythrocyte sedimentation 
rate. Very high levels of SAA were found exclusively in RA, as compared to other forms of 
arthritis (Cunnane et al., 2000). However, since then, there has been a lack of reports on SAA 
and the very early stages of RA, coupled with clinical features, including ultrasound 
measurements in larger longitudinal studies. So, the role of SAA and other accompanying 
markers will be investigated for detection of very early RA in a 3 year longitudinal study, 
alongside with development of prediction and forecast models of disease activity and 
outcome. SAA levels will also be compared between inflammatory RA and other autoimmune 
and non-autoimmune patient control groups. 
3. Development of disease models in animals. In order to determine whether renal disease is 
associated with chronic inflammation and the role of SAA in parallel with other inflammatory 
parameters, dogs naturally infected by Leishmania infantum will be used. These dogs will be 
monitored during a period of around 12 months. In addition to inflammatory markers and 
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acute phase proteins (e.g. IL-6, IL-10, IL-1β, IL2-R, IL-8, TNFα, IFNγ, CRP, haptoglobin, 
transferrin and ferritin), serum biochemistry profile, and standard indices of renal function 
(microalbuminuria, creatine, protein/creatinin ratio) will be measured at the beginning of the 
study and 1, 2, 3, 6 and 12 months after and values obtained will be correlated with those of 
SAA and other inflammatory mediators. Additionally, renal biopsies will be carried out in 
animals in order to characterize the renal lesions according to the classifications previously 
reported (Costa F.A. et al., 2000; Costa F.A. et al., 2003). 
The amelioration of inflammation by administration of anti-inflammatory drugs, such as 
leflunomide, methotrexate and NSAIDS will be determined. A comparison will be made 
between acute and chronic inflammatory models, as well as immuno-mediated inflammation 
and neoplasia models. 
4. Determination of how SAA functions as a potential therapeutic agent in viral 
infections using recently developed assays and culture systems (Wakita T. et al., 2005; 
Bartosch B. et al., 2003). Briefly, a series of peptides derived from SAA will be designed 
based on their predicted secondary structures (Uhlar C.M. et al., 1999) and their potential 
antiviral activity. For their antiviral functions, they will be analyzed in cell culture with the 
hepatitis C virus (HCVcc) using in vitro culture/infectivity assay system. The most potent 
peptides will then be used to characterize their mechanism of action. These assays will allow 
us to study directly the efficiency of antivirals, predict and follow the emergence of resistant 
mutants and investigate many other therapeutic relevant issues, such as antiviral synergy.  
5. Determination of how SAA functions as a potential therapeutic agent in bacterial 
infections will be based on previously developed assays (Hari-Dass R. et al., 2005; Shah C. et 
al., 2006). SAA isoforms will be separated and examined for their ability to bind to selected  
bacteria and opsonize them (SAA-coated fluorescent beads and SAA opsonised ligand-coated 
fluorescent beads will be used). Studies will be performed to determine the regions of SAA 
responsible for binding to bacteria and responsible for binding to macrophages thus leading to 
phagocytosis. Initially, we will determine which naturally occurring human isoforms are 
responsible for binding to particularly important pathogenic Gram-negative bacteria (e.g. E. 
coli, Campylobacter jejuni, Klebsiella pneumonia, Vibrio cholera and Salmonella sp.). 
Potential antibacterial agents will be used in direct bacterial survival assays and in bacterial 
and epithelial cell cultures to determine the mechanism of protection as observed in previous 
data (Eckhardt E.R. et al., 2010).  
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6. High throughput studies: Dedicated and whole genome microarrays will be screened for 
novel inflammatory markers (Fon Tacer K. et al., 2007; Rezen T. et al., 2007), as well as 
potent novel anti-inflammatory compounds determined based on their inhibitory effects in 
human cellular models. In addition to ELISA, Western blotting and flow cytometry, genomics 
and transcriptomics will be used to determine the consequences of SAA binding to human 
primary cells at transcriptional and translational levels. An advantage of this approach is the 
likely identification of additional molecules capable of binding SAA on cellular surfaces. All 
these assays will be performed using different SAA isoforms and identified genetic variants. 
Identifying receptors/pathways by which these isoforms can change the physiological 
functions of human primary cells will provide important targets for therapeutic intervention. 
This knowledge will also guide development of appropriate interventions either by using 
existing anti-inflammatory drugs or by employing novel therapeutic strategies (e.g. isolated 
compounds from marine microorganisms).  
7. Bioinformatics-Data integration and modeling:  
The network will identify clusters of inflammation-associated biomarkers of intermediate, 
well-defined specificity (markers with absolute specificity are rare or non-existing) and we 
anticipate that future chronic inflammatory disease diagnosis, prognosis and monitoring will 
rely on using computer algorithms of multiple markers, among them SAA. 
Integration of heterogenous high-throughput (e.g. microarrays) and low-throughput (qPCR, 
Western blots, FACS) datasets is of utmost importance not only in discovering novel 
molecular components using model systems, but also in identifiying predictive markers using 
clinical samples. Therefore major thrust in this work package will be directed towards the 
management and integration of the generated data sets through the development of dedicated 
database and interfacing the database with analytical tools. Additionally, the power of 
mathematical modeling will be exploited to prioritize the candidate genes for further 
functional studies (example publications: Pages F. et al., 2005; Galon J. et al., 2006 and Hackl 
H. et al., 2005).  
8. Neutralization and identification of lead therapeutic antibodies is planned in parallel to 
all experiments. Existing and newly isolated SAA-specific antibodies and sera will be 
assessed for their ability to neutralise SAA activity. We will map the epitopes recognized by 
isolated neutralizing and non-neutralizing antibodies and determine whether they are 
conserved across genotypes, if they are linear or conformational, using competition enzyme 
immunoassays against native and denatured proteins and immunoassays using a panel of 
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point-mutated envelope proteins. The ability of monoclonal antibodies demonstrating a broad 
neutralizing capability to prevent pro-inflammatory activation or to neutralize SAA’s 
protective function in infections will be assessed using in vitro assays, both alone and in 
combination, to determine whether or not synergy exists. 
Lastly, the network will determine the threshold concentration and milieu conditions 
necessary for the transition of SAA’s protective anti-infective function to one of degradative 
chronic nature. 
 
Partner centers in CODI-STRAT network 
Each of the following partners has long-standing experiences in their specialties, and can 
develop unique approaches appropriate for the identification of novel inflammatory and 
infective therapy strategies. By taking advantage of the great synergy that exists across the 
network, this integrated approach is unique and will ensure training and scientific success.   
The network spans 7 European countries (5 from the Mediterranean, namely Spain, France, 
Italy, Malta and Slovenia) (Figure 4) and the USA.  
 
 
Figure 4: Distribution of network partners across Europe. 
• Austria (TUG) 
• France (CNRS) 
• Italy (SMVL) 
• Malta (UoM) 
• Slovenia (UMC-Lj, UL; IEDC, IR) 
• Spain (UM, Biomar; BIOIBERICA) 
• United Kingdom (LSHTM, QMUL) 
 
Some of the countries are emerging economies, such as Slovenia and Malta, which have 
witnessed a steady increase of student numbers from neighbouring countries and the growing 
demand for training in disciplines such as bioinformatics, genomics, transcriptomics, 
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biopharmaceuticals, state of the art culture and expression systems and biotechnology. The 
network is multi-disciplinary and multi-sectorial (with industry partners/small and medium-
sized enterprises, from the biopharmaceutical and nutritional fields), with excellence in 
science, research and training as high priorities, keeping closely connected to the clinical and 
biotechnical/pharmaceutical environments. Clearly important is the role of the newly formed 
smaller institutions, such as the Institute for Rheumatology composed of practicing 
physicians, diagnostic experts, research specialists and professors with the interdisciplinary 
knowledge and flexibility necessary for the advancement of science development, 
transparency and support.  
There is evidence of growing successful collaboration between the partners of the CODI-
STRAT network in terms of common publications (Lakota K. et al., 2011; Erman A. et al., 
2011), as well as the 3-day attendance of the network at the SAA workshop (2010) held in 
IEDC-Bled School of Management (Slovenia). Prior and current collaborations have already 
led to exchanges of reagents and know-how.  The specific partner roles in CODI-STRAT are 
briefly explained below. 
Full Partners: 
P1: The University of Primorska, Faculty of Mathematics, Natural Sciences and Information 
Technology (UP-FAMNIT), Slovenia  
UP-FAMNIT represents a University/Faculty with a priority for integrated science knowledge 
in research and teaching, student and faculty academic excellence, autonomy and freedom 
towards achieving open, independent and international development. One of the goals of UP-
FAMNIT is to become a reference University/Faculty locally, as well as in the Mediterranean 
and southeast Europe. Roles in CODI-STRAT: mathematical modelling, bioinformatics and 
education.  
P2: The University Medical Centre-Ljubljana (UMC-LJ), Slovenia  
The UMC-LJ is the largest public medical institution (over 7000 staff, composed of clinicians, 
nurses, researchers and support staff) in Slovenia promoting clinical excellence/ 
research/education for the benefit of patients. The Department of Rheumatology (with ∼50 
employees) provides the diagnostics, prognostics with the support of a fully functional routine 
and research laboratory (also measuring SAA routinely). Roles in CODI-STRAT: network 
coordination, clinical research and molecular/cellular studies. 
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P3: Centre national de la recherche scientifique (CNRS), Institut Pasteur de Lille, France 
The CNRS is a public basic-research agency producing knowledge, and making it available to 
society. More than 1,000 research units spread throughout France cover all fields of research. 
The Hepatitis C Laboratory (HCL) is located on campus - Pasteur Institute of Lille is a first-
rate institute renowned worldwide for its high standard in medical research, especially in the 
field of infectious diseases. HCL is a classical laboratory of virology containing P2 and P3 
facilities with access to common facilities used for projects. HCL has trained 8 MS students 
and 10 PhD students, as well as 12 Post-Docs. Roles in CODI-STRAT: infectious diseases, 
viral models, hepatitis studies and anti-viral agents. 
P4: University of Malta Medical School (UoM), Department of Pathology, Faculty of 
Medicine and Surgery, Malta 
UoM is one of the oldest medical schools in Europe (founded 1676) which became University 
Faculty in 1771. The Department of Pathology is responsible for undergraduate teaching in all 
pathology disciplines, research as well as servicing medical, dental, pharmacy, health science 
courses. Offers postgraduate training, including MSc Biomedical Sciences (10 in 2007), 
collaborates closely with the Department Pharmacology & Therapeutics. Roles in CODI-
STRAT: clinical studies, genetics and asthma research. 
P5: University of Murcia (UM), Department of Veterinary Medicine and Surgery (DVM), 
Spain 
The University of Murcia has ∼ 40.000 students and 6000 staff and has recently being 
recognized as an University of Excellence by the Spanish Ministry of Education. The 
Department of Animal Medicine and Surgery (with over 60 employees) specializes in the 
veterinary sciences, provides teaching services and is a referral diagnostic service to small and 
large animal medicine. UM-DVM also specializes in the application of acute phase proteins 
as markers of disease, as well as indicators of disease progression, with development of 
sensitive immunoturbidimetric assays, production of antibodies and characterization of SAA 
expression in healthy and pathological samples. Roles in CODI-STRAT: veterinary studies 
and animal models of infectious diseases. 
P6: Graz University of Technology (TUG), Institute for Genomics and Bioinformatics (IGB), 
Austria 
The Institute is committed to generation, management, and leveraging of high-throughput data 
from genomic studies. Activities include bioinformatic education/services, development of 
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databases and tools for genomic data computational analysis. Methodology and equipment 
include: New algorithms prototyped in Matlab, R, Bioconductor or BioPerl based on 
established computational methods. After successful validation, algorithms - implemented. 
Current computational infrastructure at IGB consists of Storage Area network, with 11 TB, 
NAS system (1TB), 24 node dual 32-bit CPU computing cluster, seven 64-bit Opteron servers 
covering databases/ application services/computational analysis tasks. Staff and training 
experience include: IGB personnel includes 6 bioinformaticians at post-doc level and 8 at 
Ph.D. student level. In the past five years, 15 early stage researchers received successful PhD 
training. Roles in CODI-STRAT: Bioinformatics and computational analyses.  
P7: Queen Mary University of London, William Harvey Research Institute (WHRI), UK  
WHRI, Queen Mary, University of London, is the largest pharmacological Institute in the UK, 
rated top 20 pharmacological research centres worldwide. WHRI is a state of the art 
environment (∼ 340 researchers) for inflammation and cardiovascular research.  The Centre 
for Biochemical Pharmacology at the WHRI, is formed by 25 scientists and students; is 
equipped with 4 cell culture units, radioactive room, intravital microscopy facility, a flow 
chamber system etc. Close by, are state-of-the-art animal facilities, flow cytometry, Genome 
center and Proteomic Unit. Roles in CODI-STRAT: pharmacology, inflammation, 
biochemistry and molecular/cellular models. 
P8: London School of Hygiene and Tropical Medicine (LSHTM), Department of Infectious 
and Tropical Diseases, UK  
The London School of Hygiene & Tropical Medicine is internationally renowned in public 
health and tropical medicine, a leading postgraduate medical institution in Europe and 
Britain's national school of public health. The Department of Infectious & Tropical Diseases 
(∼ 300 staff) is highly multidisciplinary with many MSc courses, including the well-
established MSc in Immunology of Infectious Disease. Immunology unit (∼ 70 staff) has a 
research focus on understanding infectious diseases. Roles in CODI-STRAT: infectious 
diseases and anti-bacterial agents. 
P9: Instituto BioMar S.A. 
Instituto Biomar, (founded in 1996) as a spin-out of the biopharmaceutical company 
PharmaMar, has its own building facilities in the Parque Tecnológico de León (Leon’s 
Technological park). Last capital expansion was in 2006 and welcomed new investors. 
Instituto Biomar is a R&D service company working in discovery/development of natural 
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marine compounds for the treatment of different Human Health applications. The company 
has expertise in Marine Microbiology and Natural Products Chemistry, has generated large 
collection of natural extracts (over 35,000) from the fermentation of the marine 
microorganisms and a library of natural compounds (2000 entries). Its microbial strain 
collection is also being evaluated for other industrial applications. Roles in CODI-STRAT: 
biophamaceuticals, anti-inflammatory and anti-infective natural extracts. 
Associate partners: 
API. IEDC– Bled School of Management 
IEDC – Bled School of Management was founded in 1986 as the first proper business school 
in Central and Eastern Europe. Over the years, it has offered more than 900 management and 
executive education programs to more than 50,000 managers from over 70 countries. The 
range of programs covers short executive development seminars and workshops and longer 
executive education programs, tailor-made programs for corporate partners, three MBA 
degree programs and a PhD program. The school accepts about 3500 program participants a 
year, 80% of whom come from countries other than Slovenia. Although the majority of the 
participants come from the corporate world, IEDC has offered a number of programs for 
managers of healthcare institutions and from cultural organizations, as well as public 
administration. Roles in CODI-STRAT: management and executive education. 
APII. BIOIBERICA S.A., Spain 
Bioiberica specializes in nutrition, osteoarthritis pharmacology, joint care and chondro-
protection and is dedicated to biomolecular research. Roles in CODI-STRAT: pharmacology 
and consulting. 
APIII. University of Ljubljana (UL) 
A. Faculty of Medicine, Institute of Cell Biology - ICB 
ICB is a facility/training site for microscopy of biological material. The facilities include 
transmission and scanning electron microscopy, light microscopy including life cell imaging, 
optical sectioning and microinjection device. ICB personnel include 9 PhD/Univ. biologists 
and 4 technicians.  Role in CODI-STRAT: imaging specialists. 
B. Faculty of Medicine, Centre for Functional Genomic and Bio-Chips (CFGBC), Slovenia 
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CFGBC is joint venture of UL & Consortium-Bio-Chips with Slovenian microarray 
facility/training site. The facilities include state of the art spotting arrays, oligo- and cDNA 
microarrays, an automatic hybridization station, scanners, high throughput RT-PCR, 
computers and software for data capturing data/interpretation. CFGBC personnel includes 10 
PhD/Univ. biochemists/molecular biologists, 1 PhD bioinformatician, and a technician. In 
past ten years, 10 young investigators have received successful PhD training. Roles in CODI-
STRAT: genomics, transcriptomics and biochips. 
APIV. The Institute of Rheumatology (IR) 
IR was established recently with the primary objectives of providing excellence in healthcare, 
diagnostics, research and education of chronic rheumatic diseases for the advancement of 
preventive, predictive, personalized and participatory medicine. Role in CODI-STRAT: 
management and clinical research consulting. 
APV. University of Utah, USA (UU) 
The University of Utah is recognized as a world leader in research, having the overall goals of 
advancing the frontiers of knowledge, enriching society, and serving the greater good. To 
meet these goals, the University actively promotes the recruitment of world-class scientists 
through various programmes and substantial investment into core facilities, state-of-the-art 
equipment, and support personnel needed to carry out cutting edge research. The UU’s 
research and scholarly activity is ranked 80th in the world and 47th in the United States in the 
2009 Academic Ranking of World Universities (www.arwu.org/ARWU2009.jsp). Also in 
2009, the UU was ranked among the top 25 public U.S. research universities and among the 
top 50 U.S. research universities overall (Top American Research Universities report; 
www.mup.asu.edu/research.html). Specific emphasis on advancing human health issues is 
evident from our internationally recognized research in the areas of microbial pathogenesis, 
immunology and cell biology within the Division of Microbiology and Immunology (~26 
faculty) in the Pathology Department. Roles in CODI-STRAT: infectious diseases, 
microbiology and animal models.  
APVI. San Marco Veterinary Laboratory (SMVL) 
SMVL is the largest veterinary laboratory in Italy, specializing in animal care and acute phase 
proteins. SMVL has a strong interest in clinical research and dissemination of scientific 
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knowledge to veterinary doctors. Roles in CODI-STRAT: veterinary studies, animal models 
and animal care. 
 
CONCLUSIONS 
There is urgency for the development of novel, effective and safer anti-inflammatory drugs 
and anti-infectious agents, making this network more than timely. This coordinated cohort 
effort can provide novel strategies for rapid development of anti-inflammatory drugs and anti-
infectious agents to the Mediterranean region, as well as broader European and international 
communities. This network will work to develop the necessary multi-disciplinary and multi-
sectorial approach to bring about the rapid development of detection kits and therapeutics 
leading from bench to the bedside, resulting in improved health and welfare together with 
significant direct and indirect economic, as well as social benefits.  
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